DIGOXIN injection labels and packages: Difference between revisions

Revision as of 04:40, 13 March 2014

Digoxin
DIGOXIN injection^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
DIGOXIN tablet^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

For patient information, click here.

08-2013M

D46118410

Manufactured in Canada by

Sandoz Canada Inc. for

Sandoz Inc., Princeton, NJ 08540

500 mcg (0.5 mg) per 2 mL Carton

NDC 0781-3059-95

Digoxin Injection, USP

500 mcg (0.5 mg)/2 mL

[250 mcg (0.25 mg)/mL]

Sterile

For Intravenous or Intramuscular Injection

Dilution not required

Rx only

5 x 2 mL Ampules

SANDOZ

@@ Line 5: / Line 5: @@
 '''''For patient information, click <u>[[Digoxin (patient information)|here]]'''''</u>.
+==Labels and Packages==
 -2013M